Cabaletta Bio (CABA) Competitors $1.84 +0.03 (+1.66%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.87 +0.03 (+1.58%) As of 07:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CABA vs. PVLA, ORGO, GOSS, MGTX, XNCR, ORKA, OPT, ARVN, ATYR, and PRMEShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Palvella Therapeutics (PVLA), Organogenesis (ORGO), Gossamer Bio (GOSS), MeiraGTx (MGTX), Xencor (XNCR), Oruka Therapeutics (ORKA), Opthea (OPT), Arvinas (ARVN), aTyr Pharma (ATYR), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. Its Competitors Palvella Therapeutics Organogenesis Gossamer Bio MeiraGTx Xencor Oruka Therapeutics Opthea Arvinas aTyr Pharma Prime Medicine Cabaletta Bio (NASDAQ:CABA) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Which has more risk and volatility, CABA or PVLA? Cabaletta Bio has a beta of 2.86, indicating that its share price is 186% more volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500. Which has stronger earnings & valuation, CABA or PVLA? Palvella Therapeutics has higher revenue and earnings than Cabaletta Bio. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$115.86M-$2.71-0.68Palvella Therapeutics$42.81M14.68-$17.43M-$12.10-4.70 Does the media favor CABA or PVLA? In the previous week, Palvella Therapeutics had 8 more articles in the media than Cabaletta Bio. MarketBeat recorded 10 mentions for Palvella Therapeutics and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.79 beat Palvella Therapeutics' score of 0.59 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Palvella Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CABA or PVLA? Cabaletta Bio currently has a consensus target price of $14.50, indicating a potential upside of 688.04%. Palvella Therapeutics has a consensus target price of $60.91, indicating a potential upside of 7.16%. Given Cabaletta Bio's higher probable upside, equities research analysts plainly believe Cabaletta Bio is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Is CABA or PVLA more profitable? Palvella Therapeutics' return on equity of -62.30% beat Cabaletta Bio's return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -92.11% -74.08% Palvella Therapeutics N/A -62.30%-43.34% Do insiders & institutionals believe in CABA or PVLA? 40.1% of Palvella Therapeutics shares are held by institutional investors. 11.3% of Cabaletta Bio shares are held by company insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryPalvella Therapeutics beats Cabaletta Bio on 9 of the 14 factors compared between the two stocks. Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$168.29M$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-0.6821.5775.3926.02Price / SalesN/A254.90460.5891.38Price / CashN/A44.4425.8129.91Price / Book0.599.6112.836.25Net Income-$115.86M-$53.29M$3.29B$270.76M7 Day Performance9.52%0.57%0.85%2.54%1 Month Performance7.60%4.56%4.68%5.73%1 Year Performance-55.23%10.44%70.14%25.85% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio3.0683 of 5 stars$1.84+1.7%$14.50+688.0%-55.2%$168.29MN/A-0.6850Positive NewsPVLAPalvella Therapeutics1.8805 of 5 stars$55.02-1.2%$58.50+6.3%N/A$608.52MN/A-4.55N/AORGOOrganogenesis3.9972 of 5 stars$4.77-4.6%$7.50+57.2%+75.4%$605.12M$482.04M-34.07950Positive NewsGOSSGossamer Bio3.9708 of 5 stars$2.66-9.5%$8.50+219.5%+275.5%$604.83M$114.70M-4.29180Trending NewsAnalyst UpgradeHigh Trading VolumeMGTXMeiraGTx4.1926 of 5 stars$7.47-2.9%$24.00+221.3%+79.1%$600.96M$33.28M-3.66300Positive NewsXNCRXencor3.9459 of 5 stars$8.41-1.6%$22.25+164.6%-59.9%$599.80M$110.49M-3.50280Positive NewsORKAOruka Therapeutics2.0802 of 5 stars$15.80-3.4%$40.38+155.5%-38.1%$591.71MN/A-5.62N/AOPTOpthea0.4809 of 5 stars$3.41+7.2%$1.33-60.9%N/A$583.11M$30K0.008Gap UpARVNArvinas2.9994 of 5 stars$7.94+1.4%$19.76+148.9%-69.1%$582.96M$263.40M-7.86420Positive NewsATYRaTyr Pharma2.5673 of 5 stars$5.46-2.7%$23.25+325.8%+217.4%$535.03M$230K-6.8253Trading HaltedPRMEPrime Medicine3.5222 of 5 stars$3.89+4.6%$8.92+129.2%-0.5%$523.49M$4.96M-1.90234 Related Companies and Tools Related Companies PVLA Competitors ORGO Competitors GOSS Competitors MGTX Competitors XNCR Competitors ORKA Competitors OPT Competitors ARVN Competitors ATYR Competitors PRME Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CABA) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CABA Stock Alerts